JP2019508429A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508429A5
JP2019508429A5 JP2018545198A JP2018545198A JP2019508429A5 JP 2019508429 A5 JP2019508429 A5 JP 2019508429A5 JP 2018545198 A JP2018545198 A JP 2018545198A JP 2018545198 A JP2018545198 A JP 2018545198A JP 2019508429 A5 JP2019508429 A5 JP 2019508429A5
Authority
JP
Japan
Prior art keywords
inhibitor
ovarian cancer
dna damage
patient
repair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018545198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508429A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/019843 external-priority patent/WO2017151554A1/en
Publication of JP2019508429A publication Critical patent/JP2019508429A/ja
Publication of JP2019508429A5 publication Critical patent/JP2019508429A5/ja
Priority to JP2022053212A priority Critical patent/JP2022079569A/ja
Priority to JP2024019509A priority patent/JP2024054312A/ja
Pending legal-status Critical Current

Links

JP2018545198A 2016-02-29 2017-02-28 卵巣がんの処置のための併用療法 Pending JP2019508429A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022053212A JP2022079569A (ja) 2016-02-29 2022-03-29 卵巣がんの処置のための併用療法
JP2024019509A JP2024054312A (ja) 2016-02-29 2024-02-13 卵巣がんの処置のための併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301225P 2016-02-29 2016-02-29
US62/301,225 2016-02-29
PCT/US2017/019843 WO2017151554A1 (en) 2016-02-29 2017-02-28 Combination therapy for treatment of ovarian cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022053212A Division JP2022079569A (ja) 2016-02-29 2022-03-29 卵巣がんの処置のための併用療法

Publications (2)

Publication Number Publication Date
JP2019508429A JP2019508429A (ja) 2019-03-28
JP2019508429A5 true JP2019508429A5 (cg-RX-API-DMAC7.html) 2020-04-09

Family

ID=59744380

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018545198A Pending JP2019508429A (ja) 2016-02-29 2017-02-28 卵巣がんの処置のための併用療法
JP2022053212A Withdrawn JP2022079569A (ja) 2016-02-29 2022-03-29 卵巣がんの処置のための併用療法
JP2024019509A Pending JP2024054312A (ja) 2016-02-29 2024-02-13 卵巣がんの処置のための併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022053212A Withdrawn JP2022079569A (ja) 2016-02-29 2022-03-29 卵巣がんの処置のための併用療法
JP2024019509A Pending JP2024054312A (ja) 2016-02-29 2024-02-13 卵巣がんの処置のための併用療法

Country Status (9)

Country Link
US (1) US11154538B2 (cg-RX-API-DMAC7.html)
EP (1) EP3423048A4 (cg-RX-API-DMAC7.html)
JP (3) JP2019508429A (cg-RX-API-DMAC7.html)
CN (1) CN108697666A (cg-RX-API-DMAC7.html)
AU (2) AU2017227534A1 (cg-RX-API-DMAC7.html)
CA (1) CA3014680A1 (cg-RX-API-DMAC7.html)
IL (1) IL261195B (cg-RX-API-DMAC7.html)
MX (1) MX2018010223A (cg-RX-API-DMAC7.html)
WO (1) WO2017151554A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
KR20200106053A (ko) * 2017-12-29 2020-09-10 버텍스 파마슈티칼스 인코포레이티드 Atr 억제제를 사용한 암 치료 방법
JP2021510702A (ja) 2018-01-12 2021-04-30 プロリンクス エルエルシー 相乗的がん治療
EP3966782A2 (en) 2019-05-06 2022-03-16 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN113462784B (zh) * 2021-08-31 2021-12-10 迈杰转化医学研究(苏州)有限公司 一种构建用于同源重组修复缺陷检测的靶标集合的方法
JPWO2023157891A1 (cg-RX-API-DMAC7.html) 2022-02-16 2023-08-24
WO2024111564A1 (ja) * 2022-11-21 2024-05-30 富士フイルム株式会社 トポテカン又はその塩を内包するリポソーム組成物およびdna損傷修復阻害剤を含む組合せ医薬
CN116024162B (zh) * 2023-02-27 2025-01-10 山东大学 Egcg联合chk2抑制剂在改善卵成熟或胚胎发育中的应用
TW202502354A (zh) * 2023-06-02 2025-01-16 美商薩諾管理公司 同源重組修復缺陷(hrd)作為預測性生物標記以便使用wee1抑制劑治療癌症
CN117860753A (zh) * 2023-11-30 2024-04-12 华中科技大学 一种cdc7抑制剂化合物xl413在制备预防或治疗肝损伤和肝纤维化药物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
AU2008321382A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
EP2714038A1 (en) * 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
EP2714033A1 (en) * 2011-05-26 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
WO2013067162A1 (en) * 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2014138101A1 (en) 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (hr) deficient cancer
JP6114075B2 (ja) * 2013-03-07 2017-04-12 三菱航空機株式会社 航空機の警報システム、及び、航空機
US20160120848A1 (en) * 2013-05-21 2016-05-05 Synta Pharmaceuticals Corp. Specific cancer treatment regimes with ganetespib
DK3686288T3 (da) 2014-08-15 2023-05-22 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens

Similar Documents

Publication Publication Date Title
Livraghi et al. PARP inhibitors in the management of breast cancer: current data and future prospects
Liu et al. PARP inhibitors in ovarian cancer: current status and future promise
Heitz et al. Bevacizumab in the treatment of ovarian cancer
Li et al. Panax quinquefolium saponin attenuates cardiomyocyte apoptosis and opening of the mitochondrial permeability transition pore in a rat model of ischemia/reperfusion
Molinaro et al. Recent advances on pathophysiology, diagnostic and therapeutic insights in cardiac dysfunction induced by antineoplastic drugs
Girek et al. Novel tetrahydroacridine derivatives with iodobenzoic moieties induce G0/G1 cell cycle arrest and apoptosis in A549 non-small lung cancer and HT-29 colorectal cancer cells
JP2023175694A (ja) 2,4,6-トリフルオロ-n-[6-(1-メチル-ピペリジン-4-カルボニル)-ピリジン-2-イル]-ベンズアミドの組成物
Slator et al. Triggering autophagic cell death with a di-manganese (II) developmental therapeutic
JP2021510702A5 (cg-RX-API-DMAC7.html)
Guo et al. Pyroptosis in glioma: current management and future application
JP2019508429A (ja) 卵巣がんの処置のための併用療法
Hu et al. Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice
Payne et al. DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial
Musella et al. PARP inhibition: A promising therapeutic target in ovarian cancer
Pillai et al. PL03. 09: phase 3 study of ganetespib, a heat shock protein 90 inhibitor, with Docetaxel versus Docetaxel in advanced non-small cell lung cancer (GALAXY-2)
Murai et al. Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition
Kruse et al. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy
US20140120182A1 (en) Method for the treatment of cancer
US20250270268A1 (en) Amelioration and treatment of infarction damage
Moro-Sibilot et al. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study)
Ren et al. NCOA4-mediated ferritinophagy promotes pyroptosis by reactive oxygen species generation in the progress of gingival inflammation
Alharbi et al. DOX and MET treatment induces cognitive impairment through downregulation of IL-1-alpha and IRS-1 in the rat brain.
Abolhoda et al. Morbidity and mortality for pulmonary resections in lung cancer after induction treatment
Reck et al. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma
AR077189A1 (es) Comprimidos de ibuprofeno de sodio y procedimiento de fabricacion de composiciones farmaceuticas que incluyen ibuprofeno de sodio